SG11201802794PA - Therapeutic compounds and methods - Google Patents
Therapeutic compounds and methodsInfo
- Publication number
- SG11201802794PA SG11201802794PA SG11201802794PA SG11201802794PA SG11201802794PA SG 11201802794P A SG11201802794P A SG 11201802794PA SG 11201802794P A SG11201802794P A SG 11201802794PA SG 11201802794P A SG11201802794P A SG 11201802794PA SG 11201802794P A SG11201802794P A SG 11201802794PA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- therapeutic compounds
- therapeutic
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237835P | 2015-10-06 | 2015-10-06 | |
| PCT/US2016/055722 WO2017062604A1 (en) | 2015-10-06 | 2016-10-06 | Therapeutic compounds and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201802794PA true SG11201802794PA (en) | 2018-05-30 |
Family
ID=58488527
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912792YA SG10201912792YA (en) | 2015-10-06 | 2016-10-06 | Therapeutic compounds and methods |
| SG11201802794PA SG11201802794PA (en) | 2015-10-06 | 2016-10-06 | Therapeutic compounds and methods |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912792YA SG10201912792YA (en) | 2015-10-06 | 2016-10-06 | Therapeutic compounds and methods |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11098100B2 (en) |
| EP (2) | EP3359168A4 (en) |
| JP (3) | JP7461620B2 (en) |
| CN (1) | CN108697736A (en) |
| AU (2) | AU2016336451B2 (en) |
| BR (1) | BR112018006811A2 (en) |
| CA (1) | CA3001185A1 (en) |
| IL (1) | IL258931B (en) |
| MX (1) | MX2018004114A (en) |
| RU (1) | RU2770001C2 (en) |
| SG (2) | SG10201912792YA (en) |
| WO (1) | WO2017062604A1 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2975851A1 (en) | 2015-02-06 | 2016-08-11 | National University Of Singapore | Methods for enhancing efficacy of therapeutic immune cells |
| JP7461620B2 (en) | 2015-10-06 | 2024-04-04 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Therapeutic Compounds and Methods |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| BR112019002394B1 (en) | 2016-08-10 | 2021-12-21 | Ajou University Industry-Academic Cooperation Foundation | HETERODIMERIC PROTEIN FLUTED WITH CF AND ITS USE |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN111247241A (en) | 2017-08-10 | 2020-06-05 | 新加坡国立大学 | T cell receptor-deficient chimeric antigen receptor T cells and methods of use thereof |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
| MX2020006155A (en) * | 2017-12-12 | 2020-08-13 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease. |
| CU24545B1 (en) * | 2017-12-29 | 2021-09-07 | Ct Ingenieria Genetica Biotecnologia | ANTAGONIST PEPTIDE OF INTERLEUKIN-15 ACTIVITY |
| US20210388093A1 (en) * | 2018-10-19 | 2021-12-16 | Regents Of The University Of Minnesota | Nk engager molecules and methods of use thereof |
| SG11202104136YA (en) | 2018-10-23 | 2021-05-28 | Dragonfly Therapeutics Inc | Heterodimeric fc-fused proteins |
| CA3142159A1 (en) * | 2019-05-31 | 2020-12-03 | City Of Hope | Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies |
| CA3142483A1 (en) * | 2019-06-12 | 2020-12-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods to treat viral infections |
| US20220332780A1 (en) | 2019-09-10 | 2022-10-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| BR112022004712A2 (en) * | 2019-09-16 | 2022-06-14 | Gt Biopharma Inc | Immunotherapy compounds and methods |
| CN114502577A (en) * | 2019-09-26 | 2022-05-13 | 明尼苏达大学董事会 | NK adaptor compounds that bind viral antigens and methods of use |
| WO2021138407A2 (en) * | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| AU2021260960A1 (en) | 2020-04-22 | 2022-11-24 | Dragonfly Therapeutics, Inc. | Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins |
| CN115968378A (en) * | 2020-06-03 | 2023-04-14 | 明尼苏达大学董事会 | B7H 3-targeting proteins and methods of use thereof |
| WO2022150379A1 (en) * | 2021-01-08 | 2022-07-14 | Regents Of The University Of Minnesota | Nk cell engager molecules and methods of use |
| CN116574190A (en) | 2021-07-30 | 2023-08-11 | 启愈生物技术(上海)有限公司 | Antigen targeting, anti-CD 16A and immune effector cell activating three-function fusion protein and application thereof |
| WO2023036270A1 (en) | 2021-09-09 | 2023-03-16 | 启愈生物技术(上海)有限公司 | Antigen-targeting, anti-cd16a and immune effector cell-activating trifunctional fusion protein, and use thereof |
| WO2023225531A2 (en) * | 2022-05-16 | 2023-11-23 | Northwestern University | Il15-modified car t cells for dual targeting |
| WO2023232911A1 (en) * | 2022-05-31 | 2023-12-07 | Oncopeptides Innovation 1 Ab | Novel polypeptides |
| WO2024056862A1 (en) | 2022-09-15 | 2024-03-21 | Avidicure Ip B.V. | Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof |
| WO2024064446A2 (en) * | 2022-09-19 | 2024-03-28 | Duke University | Compositions and methods for the enhancement of immune cell activities against cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003303339A1 (en) * | 2002-12-20 | 2004-07-22 | Biogen Idec Ma Inc. | Lymphotoxin beta receptor agents in combination with chemotherapeutic agents |
| EP1583503A4 (en) * | 2002-12-20 | 2006-08-09 | Biogen Idec Inc | Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
| CN104645327A (en) | 2003-07-24 | 2015-05-27 | 依奈特制药公司 | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
| US7419667B2 (en) * | 2004-03-19 | 2008-09-02 | Morinaga Milk Industry Co. Ltd. | Drug for cancer therapy |
| ES2429340T3 (en) | 2005-03-10 | 2013-11-14 | Morphotek, Inc. | Anti-mesothelin antibodies |
| WO2008011157A2 (en) | 2006-07-20 | 2008-01-24 | The General Hospital Corporation | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting |
| JP5175864B2 (en) | 2007-01-26 | 2013-04-03 | ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション，インコーポレーテッド | Methods for detecting autoantibodies for disease detection and characterization |
| CA2697529A1 (en) * | 2007-08-24 | 2009-03-05 | Regents Of The University Of Minnesota | Receptor-targeting reagents |
| EP2332994A1 (en) | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| UY33492A (en) | 2010-07-09 | 2012-01-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
| JP5316719B2 (en) | 2010-08-03 | 2013-10-16 | 富士通株式会社 | Verification program and verification device |
| CN107880136B (en) * | 2010-09-21 | 2021-11-12 | 阿尔托生物科学有限公司 | Multimeric IL-15 soluble fusion molecules and methods of making and using the same |
| CN102251013A (en) | 2011-02-22 | 2011-11-23 | 北京市肿瘤防治研究所 | Antibody and antigen for recognizing tumor initiator cell and application thereof |
| KR102148982B1 (en) * | 2011-06-03 | 2020-08-27 | 조마 테크놀로지 리미티드 | Antibodies specific for tgf-beta |
| EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| AU2012309824A1 (en) * | 2011-09-12 | 2013-04-18 | Abbvie Biotherapeutics Inc. | Artificial NK cells and uses thereof |
| WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| US9258177B2 (en) * | 2012-08-02 | 2016-02-09 | International Business Machines Corporation | Storing a data stream in a set of storage devices |
| JP6420776B2 (en) * | 2013-03-05 | 2018-11-07 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | Engager cells for immunotherapy |
| US9879081B2 (en) * | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| JP7461620B2 (en) | 2015-10-06 | 2024-04-04 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Therapeutic Compounds and Methods |
-
2016
- 2016-10-06 JP JP2018517586A patent/JP7461620B2/en active Active
- 2016-10-06 US US15/766,067 patent/US11098100B2/en active Active
- 2016-10-06 EP EP16854310.6A patent/EP3359168A4/en not_active Withdrawn
- 2016-10-06 BR BR112018006811A patent/BR112018006811A2/en not_active Application Discontinuation
- 2016-10-06 CA CA3001185A patent/CA3001185A1/en active Pending
- 2016-10-06 CN CN201680071410.2A patent/CN108697736A/en active Pending
- 2016-10-06 EP EP22154076.8A patent/EP4056190A1/en active Pending
- 2016-10-06 SG SG10201912792YA patent/SG10201912792YA/en unknown
- 2016-10-06 MX MX2018004114A patent/MX2018004114A/en unknown
- 2016-10-06 WO PCT/US2016/055722 patent/WO2017062604A1/en active Application Filing
- 2016-10-06 SG SG11201802794PA patent/SG11201802794PA/en unknown
- 2016-10-06 RU RU2018116565A patent/RU2770001C2/en active
- 2016-10-06 IL IL258931A patent/IL258931B/en unknown
- 2016-10-06 AU AU2016336451A patent/AU2016336451B2/en active Active
-
2019
- 2019-09-05 US US16/561,627 patent/US20200087369A1/en not_active Abandoned
- 2019-09-05 US US16/561,587 patent/US11098101B2/en active Active
-
2021
- 2021-08-06 US US17/396,127 patent/US20210395326A1/en active Pending
- 2021-12-03 JP JP2021196759A patent/JP7274781B2/en active Active
-
2023
- 2023-04-25 JP JP2023071386A patent/JP7555625B2/en active Active
- 2023-09-25 AU AU2023233318A patent/AU2023233318A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016336451B2 (en) | 2023-06-29 |
| RU2018116565A3 (en) | 2020-11-03 |
| EP4056190A1 (en) | 2022-09-14 |
| WO2017062604A1 (en) | 2017-04-13 |
| EP3359168A1 (en) | 2018-08-15 |
| JP7461620B2 (en) | 2024-04-04 |
| EP3359168A4 (en) | 2019-08-07 |
| SG10201912792YA (en) | 2020-02-27 |
| RU2770001C2 (en) | 2022-04-14 |
| US11098100B2 (en) | 2021-08-24 |
| JP2023089290A (en) | 2023-06-27 |
| JP2018531939A (en) | 2018-11-01 |
| JP2022037037A (en) | 2022-03-08 |
| JP7555625B2 (en) | 2024-09-25 |
| MX2018004114A (en) | 2018-08-21 |
| KR20180057715A (en) | 2018-05-30 |
| CA3001185A1 (en) | 2017-04-13 |
| AU2016336451A1 (en) | 2018-04-26 |
| IL258931A (en) | 2018-06-28 |
| JP7274781B2 (en) | 2023-05-17 |
| CN108697736A (en) | 2018-10-23 |
| US20200148737A1 (en) | 2020-05-14 |
| US11098101B2 (en) | 2021-08-24 |
| IL258931B (en) | 2022-09-01 |
| US20210395326A1 (en) | 2021-12-23 |
| US20200087369A1 (en) | 2020-03-19 |
| US20180282386A1 (en) | 2018-10-04 |
| AU2023233318A1 (en) | 2023-10-12 |
| BR112018006811A2 (en) | 2018-10-16 |
| RU2018116565A (en) | 2019-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258931A (en) | Therapeutic compounds and methods | |
| HK1256383A1 (en) | Therapeutic agents | |
| HK1247614A1 (en) | Therapeutic compounds and uses thereof | |
| ZA201804070B (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| HK1243073A1 (en) | Therapeutic compounds and uses thereof | |
| GB201403093D0 (en) | Therapeutic compounds and their use | |
| GB201509893D0 (en) | Therapeutic agents | |
| GB201517263D0 (en) | Therapeutic agents | |
| HK1248697A1 (en) | Therapeutic compounds and uses thereof | |
| ZA201802256B (en) | Compounds and therapeutic uses thereof | |
| IL247325A0 (en) | Therapeutic methods employing noribogaine and related compounds | |
| GB201609597D0 (en) | Therapy | |
| GB201502412D0 (en) | Therapeutic use | |
| IL270011B (en) | Therapeutic compounds and methods | |
| GB201509885D0 (en) | Therapeutic agents | |
| GB201509888D0 (en) | Therapeutic agents | |
| GB201513299D0 (en) | Therapeutic agents | |
| GB201521767D0 (en) | Therapeutic agents | |
| GB201517264D0 (en) | Therapeutic agents | |
| GB201506786D0 (en) | Therapeutic use | |
| GB201618477D0 (en) | Therapy | |
| GB201615923D0 (en) | Macrophage-based therapy | |
| GB201609721D0 (en) | Cobination therapy | |
| GB201609312D0 (en) | Therapy | |
| GB201609322D0 (en) | Therapy |